Home | Welcome to Contract Pharma   
Last Updated Thursday, November 27 2014
Print

Search Results for 'Financial Report: Charles River Laboratories'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published October 7, 2014
Successfully nominates oral drug candidate for preclinical development Read More »
Newsmakers: James Foster
By Kristin Brooks, Contract Pharma
Published May 1, 2014
Charles River Labs’ CEO James Foster is looking upstream to offer clients a faster “go/no go” indicator for preclinical work Read More »
Published April 1, 2014
Stay tuned for Contract Pharma's Newsmaker interview with CEO, James Foster Read More »
By Kristin Brooks
Published March 13, 2014
Argenta and BioFocus add vitro and in vivo capabilities Read More »
By Michael A. Martorelli, Contributing Editor
Published January 22, 2013
Reviewing 2012’s M&A activity Read More »
By Gil Roth
Published October 17, 2012
Three-year pact covers safety assessment, development DMPK Read More »
Charles River’s Endotoxin Play
By Gil Y. Roth, Contract Pharma
Published October 9, 2012
CRL’s Foster Jordan on acquiring Accugenix Read More »
By Steve Snyder
Published January 24, 2011
What's going on at Charles River Labs? Read More »
By Michael Martorelli
Published November 6, 2009
Feel Better Now? Ending one year, approaching the next By Michael A. Martorelli It’s always interesting to write a column about an event that is still in my future, but will have already happened by the time you read my words. Th… Read More »
Published May 10, 2006
Kendle will acquire the Phase II-IV Clinical Services business of Charles River Laboratories International, Inc. for approximately $215 million in cash. The move will strengthen Kendle's position in the clinical development industry, adding therapeut… Read More »
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On